Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
BeOne Medicines
ViroMissile, Inc.
Tizona Therapeutics, Inc
Eli Lilly and Company
Angiex, Inc.
IDEAYA Biosciences
Eli Lilly and Company
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Innate Pharma
MOMA Therapeutics
NeoTX Therapeutics Ltd.
Exelixis
3B Pharmaceuticals GmbH
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
Eli Lilly and Company
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Columbia University
Agenus Inc.
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Astellas Pharma Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Danatlas Pharmaceuticals Co., Ltd
Pfizer
Pfizer
NGM Biopharmaceuticals, Inc
OHSU Knight Cancer Institute
Pfizer
M.D. Anderson Cancer Center
Lebanese University
Xencor, Inc.
Impact Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
MacroGenics
MacroGenics
AstraZeneca
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
MedImmune LLC
CytoMed Therapeutics Pte Ltd
Placon Therapeutics